Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Mar;83(3):216-24.
doi: 10.1007/s00109-004-0583-7. Epub 2004 Nov 17.

Increased levels of adenine nucleotide translocator 1 protein and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle

Affiliations

Increased levels of adenine nucleotide translocator 1 protein and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle

Dalila Laoudj-Chenivesse et al. J Mol Med (Berl). 2005 Mar.

Abstract

Facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant neuromuscular disorder, has been causally related to deletion of tandemly arrayed 3.3 kb repeats (D4Z4) on chromosome 4q35. Although increased expression of several 4q35 genes has been reported, two recent studies dispute this, finding no significant changes in the transcriptional level of any of the 4q35 genes, among which is the heart and muscle-specific isoform of the adenine nucleotide translocator (ANT1). We found markedly increased levels of ANT1 protein in both unaffected and affected FSHD muscles in comparison to control healthy muscles. Comparative protein expression analysis between healthy, Duchenne muscular dystrophy, and FSHD muscle shows that proteins involved in mitochondrial function and protection from oxidative stress are also reproducibly and specifically modified in all FSHD muscles, including clinically unaffected muscles. Increased ANT1 expression and mitochondrial dysfunction may thus be initial events in FSHD pathogenesis and represent potential therapeutic targets.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Exp Med. 2000 Oct 2;192(7):1001-14 - PubMed
    1. J Neuropathol Exp Neurol. 2001 Mar;60(3):302-12 - PubMed
    1. J Biol Chem. 1997 Aug 15;272(33):20313-6 - PubMed
    1. Hum Mol Genet. 2003 Nov 15;12(22):2895-907 - PubMed
    1. Am J Hum Genet. 1993 Oct;53(4):874-80 - PubMed

Publication types

Substances

LinkOut - more resources